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Context Summary:
Key objective: Can we utilize liquid biopsies to obtain prognostic information for patients with 
advanced cancers?
Knowledge generated: We demonstrate that an increasing number of genomic alterations found 
on liquid biopsy correlates with progressively worse survival in patients with gastrointestinal and 
other advanced cancers, independent of the percent ctDNA or allele fraction.
Relevance: The total number of alterations found on a liquid biopsy may be a marker of more 
aggressive tumor biology and has the potential to become a clinically meaningful, tissue-
1
agnostic biomarker for use in advanced cancers and warrants further testing in a prospective 
manner.
Revised December 23, 2019
ABSTRACT
PURPOSE: Studies have demonstrated an association between quantity of circulating 
tumor DNA (ctDNA) and poorer survival. We investigated the relationship between 
%ctDNA, total number of ctDNA alterations, and overall survival (OS) in liquid biopsies. 
PATIENTS AND METHODS: Overall, 418 patients with blood-based next generation 
sequencing (54 to 73 genes: Guardant Health) were analyzed. Eligible patients included 
those who had solid tumor malignancies and never received immunotherapy treatment, 
which may alter the survival curve in patients with high mutational burden. 
RESULTS: Patients with a high (≥5%) %ctDNA had significantly shorter OS versus those 
with intermediate (≥0.4% to <5%) or low (<0.4%) values (median OS, 7.0 vs. 14.1 vs. 
not reached (NR) months, respectively; P<.0001). Patients with a high (≥5) total number
of alterations had significantly shorter OS versus those with intermediate (≥1.46 to <5), 
low (<1.46), or no alterations (median OS 4.6 vs. 11.7 vs. 21.3 vs. NR months, 
respectively; P<.0001). The total number of alterations correlated with %ctDNA (r=0.85; 
95% CI, 0.81-0.87; P<0.0001). However, only an intermediate to high total number of 
alterations (1.46) was an independent predictor of worse OS (hazard ratio 1.96; 95% CI,
1.30-2.96; P=0.0014; multivariate analysis). 
CONCLUSION: We demonstrate that the total number of alterations and %ctDNA have 
prognostic value and correlate with one another, but only the total number of alterations 
was independently associated with survival outcomes. Our findings suggest that the total
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number of alterations in plasma may be an indicator of more aggressive tumor biology 
and therefore poorer survival.
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INTRODUCTION
Five-year survival rates are incredibly variable among cancer types, ranging from 
over 90% in prostate cancer to less than 8% in pancreas cancer, and depend heavily on 
clinical and pathologic stage 1. Although repeat tissue biopsies during the course of 
treatment or at the time of progression may provide clinically important information, 
such biopsies are not routinely performed because they can be technically difficult, time 
consuming, medically invasive, and lead to complications. On the other hand, liquid 
biopsies, or cell-free DNA (cfDNA) obtained from blood plasma that contains fragments of
circulating tumor DNA (ctDNA) shed from tumor cells into the bloodstream, can identify 
new actionable alterations and be performed repeatedly with minimal procedural risk 2–5. 
ctDNA can then be analyzed using technologies such as digital polymerase chain 
reaction (PCR) to detect specific known somatic variants (e.g., EGFR T790M) or next-
generation sequencing (NGS) that uses massive parallel sequencing to detect up to 
thousands of somatic and germline alterations in a single run 6. In addition, genomic 
alterations found on liquid biopsies are often concordant with alterations found on tissue 
biopsy when obtained within close proximity to one another 7–9.
A number of studies have demonstrated that there is an association between 
higher amounts of cfDNA or ctDNA and poorer survival, perhaps because percent ctDNA 
(%ctDNA) correlates with tumor burden 10, 11. For the most part, these reports 
dichotomized the level of cfDNA or ctDNA at a cut-point (often but not always at ~5% or 
10% ctDNA) 10, 12–18. In the case of surgical candidates, the cut-points may be lower. For 
instance, Baumgartner and colleagues found that pre-operative levels of %ctDNA 
0.25% in patients with peritoneal carcinomatosis were an independent predictor of 
shorter progression-free survival 15. 
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In the current study, we sought to more comprehensively examine the relationship
between %ctDNA versus the total number of alterations found in liquid biopsies and 
outcome. 
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MATERIALS AND METHODS
Patient Data
Overall, 418 consecutive eligible patients at the University of California San Diego 
who had NGS (54 to 73 genes: Guardant Health) performed on ctDNA derived from liquid
(blood) biopsies were analyzed. Eligible patients included those who had solid tumor 
malignancies, never received immunotherapy treatment, and were evaluable for clinical 
correlations including overall survival (OS) from ctDNA collection date. Patients had 
advanced/metastatic (stage IV) disease (except for patients with CNS tumors) at the time
of ctDNA analysis. Immunotherapy-treated patients were omitted because a correlation 
with blood or tissue tumor mutational burden has been associated with better 
immunotherapy response and might therefore alter the survival curve 19, 20. Patients with 
amplifications only in ctDNA were omitted because the %ctDNA for amplifications could 
not be determined. In addition to OS evaluation, patients’ data was also collected and 
analyzed for %ctDNA (the alteration with the highest allele fraction was calculated from 
all alterations, including variants of unknown significance (VUS)), total number of VUSs, 
and total number of alterations (which included VUSs). Percent ctDNA was evaluated as 
a continuous variable as well as using a cut-point of ≥5%, as this threshold had been 
found to be significant in prior studies 10. All studies and analyses were performed in 
accordance with the ethical guidelines of the Declaration of Helsinki and the Belmont 
Report per a University of California San Diego, Internal Review Board-approved protocol 
(NCT02478931) and the investigational treatment protocols for which the patients gave 
written consent. All human investigations were performed after approval by a local 
Human Investigations Committee and in accordance with an assurance filed with and 
approved by the Department of Health and Human Services.
ctDNA Sequencing
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Sequencing was performed by a Clinical Laboratory Improvement Amendments 
(CLIA)-certified and College of American Pathologists (CAP)-accredited clinical laboratory,
Guardant Health, Inc. (http://www.guardanthealth.com). The Guardant360 (54 to 73 
gene) panel identifies characterized and VUS tumor-related genomic alterations within 
cancer-related genes. All values for the total number of ctDNA alterations and the 
number of VUSs were corrected for the length (kilobase pairs, kbp) of DNA sequenced 
based on the date sequencing was performed and multiplied by 100 (Supplemental 
Table 1). All data was analyzed from the time of ctDNA collection from plasma (two 10-
mL blood tubes). This ctDNA assay has a sensitivity and specificity of >85% and 
>99.9999%, respectively, for detection of single-nucleotide variants in tumor tissue of 
advanced cancer patients 21. 
Statistical analysis: 
Statistical analysis was performed by PR. Hazard ratios (HR) for survival were 
calculated by comparing OS above and below cutoffs and performed from the time of 
ctDNA collection; dichotomization for each variable (i.e., total number of alterations, total
number of VUSs, %ctDNA) was performed at the median. Survival analyses were 
calculated by Kaplan-Meier analysis using log-rank (Mantel-Cox) test to generate p-
values, hazard ratios, and confidence intervals (CI). Linear regressions were performed 
using the least squares method. Multivariate analyses were conducted using the Wald 
chi-square test from a Cox proportional hazards model that included all variables with 
P≤0.05 in univariate analyses (i.e., gender, age, total number of alterations, %ctDNA), 
with the exception of VUSs because these alterations are already encompassed within 
the total number of alterations variable. Patients alive at the time of last follow up were 
censored at that date. Associations between %ctDNA and total number of alterations 
were determined using Spearman’s rank-order correlation. Bootstrapping utilizing 
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random sampling with replacement (N = 1,000 bootstrap samples) and multiple logistic 
regression analysis was performed, permitting the data of the sample study to be used 
as a surrogate for a larger population to validate the model. This method can be used 
when the sample size is too small to be split into training and validation sets and there is
no independent cross-validation cohort, as is the case in our study 22. Statistical analyses
were carried out using Graph-Pad Prism version 7.0 (San Diego, CA, USA) and R version 
3.5 (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org/).
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RESULTS
Patient Characteristics: 
This study included 418 patients who had NGS performed on plasma-derived 
ctDNA and did not receive immunotherapy treatment. The median age at diagnosis was 
60 years (range, 14-92) and the number of men (n=191/418; 46%) and women 
(n=227/418; 54%) were balanced. The most common tumor types included 
gastrointestinal (GI) (n=173/418; 41.4%), thoracic (n=94/418; 22.5%), central nervous 
system (n=51/418; 12.2%), and others (n=100/418; 23.9%) (Table 1). After correcting 
for the kbp length of DNA sequenced for each sample, the median total number of ctDNA
alterations (including VUSs) per patient was 1.46 (range, 0-78.8); the median total 
number of VUS alterations per patient was 0.66 (range, 0-64.2); and the median %ctDNA
was 0.4% (range, 0-80.3%) (Table 1). Among patients with GI tumors, the median total 
number of ctDNA alterations was 1.46 (range, 0-78.8) and the median %ctDNA was 0.5%
(range, 0-75%).
Factors Correlating with Survival in Univariate Analysis 
The following factors showed significant correlations with poorer survival in 
univariate analysis: gender, older age (dichotomized at the median of 60 years), higher 
total number of alterations/kbp DNA (dichotomized at the median of 1.46), greater 
number of VUS alterations/kbp DNA (dichotomized at the median of 0.66), and higher 
%ctDNA (dichotomized at the median of 0.4%) (Table 1). Tumor organ of origin was not 
found to be significantly correlated with differences in survival.
 Patients with %ctDNA greater than or equal to the median of 0.4% had inferior OS 
compared to those with less than 0.4% (HR, 2.04; 95% CI, 1.48-2.83; P<0.0001) (Table 
1). Furthermore, patients with a high %ctDNA (≥5%) had a significantly shorter OS 
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compared to those who had an intermediate (≥0.4% to <5%) or low (<0.4%) value 
(median OS 7.0 vs. 14.1 vs. not reached months, respectively; P<.0001) (Figure 1). 
Among patients with GI tumors, those with %ctDNA greater than or equal to the GI 
median of 0.5% had worse survival out comes (HR, 2.46; 95% CI, 1.50-4.03; P<.0001; 
Table 2). 
Likewise, patients with 1.46 total alterations/kbp DNA had statistically inferior OS 
compared to those who had less than the median of 1.46 total alterations/kbp DNA (HR, 
2.42; 95% CI, 1.75-3.36; P<0.0001) (Table 1). Patients with a high (≥5) total number of 
alterations/kbp DNA had significantly shorter OS compared to those who had an 
intermediate (≥1.46 to <5), low (<1.46), or no alterations (median OS 4.6 vs. 11.7 vs. 
21.3 vs. not reached months, respectively; P<.0001) (Figure 2). In the subset of 
patients with GI tumors, patients with greater than or equal to the median of 1.46 total 
alterations/kbp had worse survival outcomes (HR, 3.46; 95% CI, 2.09-5.72; P<0.0001; 
Table 2).  Also, a higher number of VUS alterations/kbp DNA (≥0.66) was associated 
with worse OS compared to those with a lower number (<0.66) of VUS alterations/kbp 
(HR, 1.69; 95% CI, 1.24-2.30) (Table 1, Supplemental Figure 1).
Correlation between %ctDNA and total number of alterations
The following ctDNA variables showed significant correlations with one another: 
the %ctDNA and the total number of alterations tend to increase together (r=0.85; 95% 
CI, 0.81-0.87; P<0.0001) (Figure 3) and the number of VUS alterations and total number
of alterations tend to increase together (r=0.73; 95% CI, 0.68-0.77; P<0.0001) 
(Supplemental Figure 2). To evaluate the influence of patients who had no detectable 
alterations (n=112), we performed a sensitivity analysis removing these patients from 
the correlation calculations and found that there was still a significant (albeit attenuated)
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correlation between %ctDNA and total number of alterations (r = 0.61, p<0.0001) as 
well as VUS and total number of alterations (r = 0.60, p<0.0001).
Factors Correlating with Survival in Multivariate Analysis 
After accounting for gender, age, total number of alterations, and %ctDNA, a 
multivariable Cox proportional hazard regression model showed that age, sex, and the 
total number of alterations were independently prognostic for survival (Table 1). 
Specifically, patients with a high number of alterations (1.46) compared to those with 
fewer alterations (<1.46) had worse OS (HR 1.96; 95% CI, 1.30-2.96; P=0.0014). 
Although statistically significant in univariate analysis, higher %ctDNA (0.4%) was not 
predictive of poorer survival compared to those with lower %ctDNA (<0.4%) (HR, 1.31; 
95% CI, 0.87-1.97; P=0.19) in multivariate analysis (Table 1). We also analyzed the 
subset of patients with GI tumors and found similar results. Although univariate analyses 
of the GI subset of patients showed that both a high number of alterations (1.46) and 
higher %ctDNA (0.5%) had prognostic value, only the total number of alterations (HR, 
3.23; 95% CI, 1.73-6.03; P<0.0001), not the %ctDNA (HR, 1.36; 95% CI, 0.73-2.51; 
P=0.34), was associated with worse outcomes in the multivariate model (Table 2).
Analysis with bootstrapping method
Bootstrapping with multiple logistic regression was performed on all variables with 
P  0.05 in univariate analysis, which included sex, age, total number of alterations, and 
%ctDNA. Among these characteristics, only total number of alterations was significantly 
associated with survival (P<0.0001; Table 1).
DISCUSSION
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Liquid biopsies have been incorporated into clinical practice as a means to obtain 
noninvasive molecular profiling in order to identify specific oncogenic driver mutations or
other alterations that can guide treatment selection. In this study, we evaluated the 
relationship between the total number of alterations and the %ctDNA detected by liquid 
biopsy and survival outcomes in 418 patients with advanced cancers. The objective was 
to explore the potential prognostic value of blood-based NGS. It should be noted that we 
adjusted for changes in sequencing length by correcting the total number of alterations 
and VUSs for the amount of DNA sequenced. In addition, we intentionally excluded 
patients who subsequently received immunotherapy treatment, as several studies have 
suggested that the use of immune checkpoint inhibitors may alter the survival curve in 
patients with increased tumor mutational burden 19, 20, 23.
We demonstrate that both the total number of alterations and the %ctDNA have 
prognostic value and correlate with one another, but only an intermediate to high 
(1.46) total number of alterations/kbp (and not high %ctDNA) was independently 
associated with worse survival outcomes in multivariate analysis in patients with GI 
tumors (Table 2) as well as in patients with a diverse group of advanced cancers (Table
1). These findings were then internally validated using bootstrap resampling. Our 
findings suggest that more alterations per kbp DNA detected in plasma may be a better 
indicator of more aggressive tumor biology and therefore poorer survival than %ctDNA. 
It is also plausible that the higher number of alterations and accompanying aggressive 
biology results in a higher tumor burden that yields a higher %ctDNA (rather than vice 
versa).
A strength of our study is that we utilized sequencing technology that allows for 
the detection of %ctDNA at a low level with high sensitivity and very high specificity 21, 24.
In comparison, some prior studies have utilized low-depth sequencing, which is less 
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capable at detecting ctDNA. As a result, these studies were only able to conclude that 
the presence of ctDNA was associated with worse outcomes compared to the absence of 
detectable ctDNA 14, 18, 25, 26. Indeed, Yang et al proposed that the presence or absence of 
ctDNA should be added to the TNM staging classification of tumors because it has 
diagnostic, therapeutic, and prognostic value 27.  When greater depth of ctDNA 
sequencing was used, prior studies have reported that %ctDNA is correlated with worse 
survival and also with increased tumor volume 10, 11, 14. We also demonstrated that 
%ctDNA correlates with survival measured from the time of blood draw (Figure 1), 
which suggests that the association between %ctDNA and outcomes may be more 
reflective of tumor burden.   
There are several limitations to our findings given the retrospective nature of the 
analysis. Although our study utilized a relatively large sample of 418 patients, we 
included a diverse group of advanced cancers and, therefore, our findings may not be 
applicable to certain tumor types. On the other hand, the variety of tumor types in our 
study may make our findings more generalizable across advanced cancers. However, we
also performed the analyses a cohort of 173 patients with gastrointestinal tumors and 
found similar results (Table 2). In addition, 112 patients in this study had no detectable 
%ctDNA, which may be due to low disease burden or due to limitations of the ctDNA 
sequencing technique. It should also be noted that there were different number of 
subgroups in the analysis of %ctDNA and number of ctDNA alterations; hence the 
conclusion that the total number of alterations and %ctDNA have prognostic value and 
correlate with one another, but only the total number of alterations was independently 
associated with survival outcomes will need to be further examined and validated.  Also, 
we do not know if this patient population is comparable to those who were not analyzed 
for ctDNA because physicians chose not to perform the analysis, or to patients who were 
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lost to follow up early and hence were inevaluable. Finally, patients had a diverse array 
of prior treatments, some of which could have confounded the results; patients treated 
with immunotherapy were excluded because cancers with higher mutational 
burden/number appear to do better on this modality. 
In conclusion, to our knowledge, this is the first demonstration that the total 
number of alterations and %ctDNA are highly correlated and have prognostic value. 
Nevertheless, in multivariate analysis, only the total number of alterations was 
independently predictive of overall survival. Understanding the prognostic value of 
ctDNA is important in and of itself, but also has implications as a confounder, since 
ctDNA is being utilized as a predictive marker for the efficacy of drugs such as 
immunotherapy 20. To summarize, the total number of alterations has the potential to 
become a clinically meaningful, tissue-agnostic biomarker for use in advanced cancers 
and warrants further testing in a prospective manner.
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Table 1:   Univariate and multivariate analyses of patient and ctDNA characteristics on survival (n = 418)a
Variable Group N=418 (%)
Median
OS
(month
s)
HR (95% CI)
Univariatee
P value
Univaria
te
HR (95% CI)
Multivariat
ef
P value
Multivaria
tef
P value
Bootstra
ph
Sex
Women 227 (54%) 79 ReferenceGroup
0.01
Reference
Group
0.04 0.1
Men 191 (46%) 53 1.47 (1.08 –2.00)
1.39 (1.02 -
1.89)
Age
60
years 225 (54%) 76.6
Reference
Group
6.1x10-4
Reference
Group
0.01 0.26
>60
years 193 (46%) 50.4
1.72 (1.26 –
2.34)
1.50 (1.09 -
2.05)
Tumor
Type
Gastroint
estinal 173 (41%) 54.6
1.59 (1.08 –
2.34)
0.12 Omitted
Thoracic 94 (22%) 72.7 1.28 (0.80 –2.03)
CNS 51 (12%) 61.4 1.15 (0.69 –1.94)
Otherd 100 (24%) 87.1 ReferenceGroup
(Total
Alteration
s x 100 /
kbp)b
<1.46 203 (49%) 104.8 ReferenceGroup
1.1x10-7
Reference
Group
1.4x10-3 1.8x10-5
1.46 215 (51%) 42.2 2.42 (1.75 –3.36)
1.96 (1.30 -
2.96)
18
(VUS x
100 /
kbp)b
<0.66 207 (50%) 87 ReferenceGroup
8.9x10-4 Omittedg
0.66 211 (50%) 53 1.69 (1.24 –2.30)
%ctDNAc
<0.4 195 (47%) 105 ReferenceGroup
1.6x10-5
Reference
Group
0.19 0.11
0.4 223 (53%) 50 2.04 (1.48 –2.83)
1.31 (0.87 -
1.97)
Note: All survival analyses were performed from the time of ctDNA collection
Abbreviations: CI = confidence interval; CNS = central nervous system; ctDNA = circulating tumor DNA; %ctDNA = percent 
circulating tumor DNA; HR = hazard ratio; kbp = kilobase pairs; NR = not reached; OS = overall survival; VUS = variants of 
unknown significance
a Patients treated with immunotherapy were excluded
b Dichotomization done at medians
c Dichotomization done at medians of highest %ctDNA for each patient; alteration with highest %ctDNA was calculated from all 
alterations including VUSs. Patients with only amplifications were considered inevaluable and excluded. Kbp indicates the length 
of ctDNA sequenced: (See Methods)
d Other Tumor Type includes Breast (n=29), Head and Neck (n=21), Genitourinary (n=13), Gynecologic (n=18), Neuroendocrine, 
Sarcoma, Melanoma, and Unknown Primary
e Hazard Ratio performed using log-rank
f Variables with P0.05 in univariate analysis were included in the multivariate analysis. Separate analyses were done to include 
%ctDNA, total alterations
g VUS was excluded from the multivariate analysis because it is encompassed within total alterations
h Boostrapping with multiple logistic regression analysis was conducted on characteristics with P0.05 in univariate analysis. P-
value based on 1,000 boostrap samples. 
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Table 2:   Univariate and multivariate analyses of patient and ctDNA characteristics and survival for 
gastrointestinal tumors (N = 173)a
Variable Group N=173(%)
Median
OS
(month
s)
HR (95% CI)
Univariated
P value
Univaria
te
HR (95% CI)
Multivariatee
P value
Multivaria
tee
Sex
Women 78 (45%) 19.7 Reference Group
0.025
Reference
Group
0.01
Men 95 (55%) 10.0 1.76 (1.08-2.88) 1.87 (1.13-3.06)
Age
60 years 93 (54%) 21.3 Reference Group
0.015
Reference
Group
0.02
>60 years 80 (46%) 10.3 1.83 (1.13-2.97) 1.78 (1.09-2.90)
(Total
Alterations
x 100 /
kbp)b
<1.46 75 (43%) 38.9 Reference Group
1.3x10-6
Reference
Group
2.4x10-4
1.46 98 (57%) 6.4 3.46 (2.09-5.72) 3.23 (1.73-6.03)
(VUS x
100 / kbp)b
<0.73 84 (49%) 21.3 Reference Group
2.3x10-6 Omittedf
0.73 89 (51%) 5.0 3.1 (1.95-5.02)
%ctDNAc
<0.5 86 (50%) 21.3 Reference Group
3.8x10-4
Reference
Group
0.34
0.5 87 (50%) 9.3 2.46 (1.50-4.03) 1.36 (0.73-2.51)
Note: All survival analyses were performed from the time of ctDNA collection
20
Abbreviations: CI = confidence interval; CNS = central nervous system; ctDNA = circulating tumor DNA; %ctDNA = percent 
circulating tumor DNA; HR = hazard ratio; kbp = kilobase pairs; NR = not reached; OS = overall survival; VUS = variants of 
unknown significance
a Patients treated with immunotherapy were excluded
b Dichotomization done at medians
c Dichotomization done at medians of highest %ctDNA for each patient; alteration with highest %ctDNA was calculated from all 
alterations including VUSs. Patients with only amplifications were considered inevaluable and excluded. Kbp indicates the length 
of ctDNA sequenced: (See Methods)
d Hazard Ratio performed using log-rank
e Variables with P0.05 in univariate analysis were included in the multivariate analysis. Separate analyses were done to include 
%ctDNA, total alterations
f VUS was excluded from the multivariate analysis because it is encompassed within total alterations
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Figure 1: Overall survival from ctDNA collection according to %ctDNA (n=418). Low to 
intermediate %ctDNA was dichotomized at the median of 0.4%. Intermediate to high 
%ctDNA was dichotomized at 5% because it had been found to be significant in prior 
studies [10]. The %ctDNA for each patient was calculated using the alteration with the 
highest allele fraction, including VUSs.
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Figure 2: Overall survival from ctDNA collection according to total alterations, including 
VUS (n=418). Low to intermediate number of alterations was dichotomized at the 
median of 1.46 alterations. 
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Figure 3: Spearman correlation between %ctDNA and total number of alterations 
(n=418).
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Supplemental Table 1: Guardant360 ctDNA NGS panel and length of DNA sequenced.
Number of Patients 
Analyzed
Number of 
Genes
Panel Start Date Size
47 54 2014 78 kbp
140 68 February 2015 137 kbp
174 70 October 2015 137 kbp
56 73 November 2016 151 kbp
1 73 September 2017 167 kbp*
*Version 2 of the 73 gene panel with no changes to reportable results
25
Supplemental Figure 1: Spearman correlation between VUS and total alterations 
(n=418). 
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Supplemental Figure 2: Overall survival from the date of ctDNA collection according to
VUS (n=418). Dichotomization for low to intermediate number of alterations was done at
the median of 0.7.
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Supplemental Figure 3: Overall survival from ctDNA collection according to total 
alterations, including VUS (n=173), for the gastrointestinal patients only. Low to 
intermediate number of alterations was dichotomized at the median of 1.46.
28
Supplemental Figure 4: Overall survival from ctDNA collection according to %ctDNA 
(n=173). Low to intermediate %ctDNA was dichotomized at the median of 0.5%. 
Intermediate to high %ctDNA was dichotomized at 5% because it had been found to be 
significant in prior studies [10]. The %ctDNA for each patient was calculated using the 
alteration with the highest allele fraction, including VUSs.
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Overall survival in GI patients according to %ctDNA (n=173)
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